Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
ABSTRACT Peritoneal carcinomatosis (PC) indicates advanced stage cancer, which is generally associated with a poor outcome and a 6 to 12 months. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for treating patients with primary PC, such as mesothelioma...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Colégio Brasileiro de Cirurgiões
2023-04-01
|
| Series: | Revista do Colégio Brasileiro de Cirurgiões |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912023000100212&tlng=pt |
| _version_ | 1797844855995498496 |
|---|---|
| author | JAIRO SEBASTIÁN ASTUDILLO VALLEJO FABIO LOPES DE QUEIROZ ANTÔNIO LACERDA FILHO PAULO ROCHA FRANÇA NETO BRENO XAIA MARTINS DA COSTA RODRIGO ALMEIDA PAIVA SILVÉRIO LEONARDO MACEDO GARCIA SERGIO BOTREL SILVA |
| author_facet | JAIRO SEBASTIÁN ASTUDILLO VALLEJO FABIO LOPES DE QUEIROZ ANTÔNIO LACERDA FILHO PAULO ROCHA FRANÇA NETO BRENO XAIA MARTINS DA COSTA RODRIGO ALMEIDA PAIVA SILVÉRIO LEONARDO MACEDO GARCIA SERGIO BOTREL SILVA |
| author_sort | JAIRO SEBASTIÁN ASTUDILLO VALLEJO |
| collection | DOAJ |
| description | ABSTRACT Peritoneal carcinomatosis (PC) indicates advanced stage cancer, which is generally associated with a poor outcome and a 6 to 12 months. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for treating patients with primary PC, such as mesothelioma, or secondary PC, such as colorectal cancer (CRC) or pseudomixoma. Until recently, such patients were deemed untreatable. Objective: The purpose of this study was to assess the results of CRS + HIPEC in patients with PC. Postoperative complications, mortality and survival rates were evaluated according to the diagnosis. Results: Fifty-six patients with PC, undergoing full CRS + HIPEC between October 2004 and January 2020, were enrolled. The mortality rate was 3.8% and the morbidity rate was 61.5%. Complications were significantly higher in proportion to the duration of surgery (p<0.001). The overall survival rates, as shown in the Kaplan-Meyer curve, were respectively 81%, 74% and 53% at 12, 24 and 60 months. Survival rates according to each diagnosis for the same periods were 87%, 82% and 47% in patients with pseudomixoma, and 77%, 72% and 57% in patients with CRC (log-rank 0.371, p=0.543). Conclusion: CRS with HIPEC is an option for pacients with primary or secondary PC. Although complication rates are high, a longer survival rate may be attained compared to those seen in previously published results; in some cases, patients may even be cured. |
| first_indexed | 2024-04-09T17:29:07Z |
| format | Article |
| id | doaj.art-43db3a230428473f8599939ea593adac |
| institution | Directory Open Access Journal |
| issn | 1809-4546 |
| language | English |
| last_indexed | 2024-04-09T17:29:07Z |
| publishDate | 2023-04-01 |
| publisher | Colégio Brasileiro de Cirurgiões |
| record_format | Article |
| series | Revista do Colégio Brasileiro de Cirurgiões |
| spelling | doaj.art-43db3a230428473f8599939ea593adac2023-04-18T07:31:51ZengColégio Brasileiro de CirurgiõesRevista do Colégio Brasileiro de Cirurgiões1809-45462023-04-015010.1590/0100-6991e-20233421-enAssessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapyJAIRO SEBASTIÁN ASTUDILLO VALLEJOhttps://orcid.org/0000-0001-5174-0322FABIO LOPES DE QUEIROZhttps://orcid.org/0000-0002-5061-9552ANTÔNIO LACERDA FILHOhttps://orcid.org/0000-0003-0789-7626PAULO ROCHA FRANÇA NETOhttps://orcid.org/0000-0001-6945-3401BRENO XAIA MARTINS DA COSTAhttps://orcid.org/0000-0001-5739-6219RODRIGO ALMEIDA PAIVAhttps://orcid.org/0000-0001-8955-8112SILVÉRIO LEONARDO MACEDO GARCIAhttps://orcid.org/0000-0001-5583-6276SERGIO BOTREL SILVAhttps://orcid.org/0000-0001-9426-9737ABSTRACT Peritoneal carcinomatosis (PC) indicates advanced stage cancer, which is generally associated with a poor outcome and a 6 to 12 months. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for treating patients with primary PC, such as mesothelioma, or secondary PC, such as colorectal cancer (CRC) or pseudomixoma. Until recently, such patients were deemed untreatable. Objective: The purpose of this study was to assess the results of CRS + HIPEC in patients with PC. Postoperative complications, mortality and survival rates were evaluated according to the diagnosis. Results: Fifty-six patients with PC, undergoing full CRS + HIPEC between October 2004 and January 2020, were enrolled. The mortality rate was 3.8% and the morbidity rate was 61.5%. Complications were significantly higher in proportion to the duration of surgery (p<0.001). The overall survival rates, as shown in the Kaplan-Meyer curve, were respectively 81%, 74% and 53% at 12, 24 and 60 months. Survival rates according to each diagnosis for the same periods were 87%, 82% and 47% in patients with pseudomixoma, and 77%, 72% and 57% in patients with CRC (log-rank 0.371, p=0.543). Conclusion: CRS with HIPEC is an option for pacients with primary or secondary PC. Although complication rates are high, a longer survival rate may be attained compared to those seen in previously published results; in some cases, patients may even be cured.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912023000100212&tlng=ptMortalitySurvivalPeritoneal DiseasesCytoreduction Surgical ProceduresHyperthermic Intraperitoneal Chemotherapy |
| spellingShingle | JAIRO SEBASTIÁN ASTUDILLO VALLEJO FABIO LOPES DE QUEIROZ ANTÔNIO LACERDA FILHO PAULO ROCHA FRANÇA NETO BRENO XAIA MARTINS DA COSTA RODRIGO ALMEIDA PAIVA SILVÉRIO LEONARDO MACEDO GARCIA SERGIO BOTREL SILVA Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Revista do Colégio Brasileiro de Cirurgiões Mortality Survival Peritoneal Diseases Cytoreduction Surgical Procedures Hyperthermic Intraperitoneal Chemotherapy |
| title | Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| title_full | Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| title_fullStr | Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| title_full_unstemmed | Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| title_short | Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| title_sort | assessing morbidity mortality and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| topic | Mortality Survival Peritoneal Diseases Cytoreduction Surgical Procedures Hyperthermic Intraperitoneal Chemotherapy |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912023000100212&tlng=pt |
| work_keys_str_mv | AT jairosebastianastudillovallejo assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT fabiolopesdequeiroz assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT antoniolacerdafilho assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT paulorochafrancaneto assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT brenoxaiamartinsdacosta assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT rodrigoalmeidapaiva assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT silverioleonardomacedogarcia assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT sergiobotrelsilva assessingmorbiditymortalityandsurvivalinpatientswithperitonealcarcinomatosisundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy |